A potential new imaging agent for early diagnosis of most serious skin cancer
Key points
- Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer.
- Ivan Greguric and colleagues working within the Cooperative Research Consortium for Biomedical Imaging Develop, an Australian Government funded research group, note that about 130,000 new cases of malignant melanoma occur each year worldwide.
- The scientists' search for better ways of diagnosis led them to a new group of radioactive imaging agents, called fluoronicotinamides, which they tested in laboratory mice that had melanoma.
- The most promising substance revealed melanoma cells with greater accuracy than imaging agents now in use, the scientists note.
Scientists in Australia are reporting development and testing in laboratory animals of a potential new material for diagnosing malignant melanoma, the most serious form of skin cancer. Their study is scheduled for the September 10 issue of the ACS' Journal of the Medicinal Chemistry, a bi-weekly publication.
Ivan Greguric and colleagues working within the Cooperative Research Consortium for Biomedical Imaging Develop, an Australian Government funded research group, note that about 130,000 new cases of malignant melanoma occur each year worldwide. Patients do best with early diagnosis and prompt treatment. The positron emission tomography (PET) scans sometimes used for diagnosis sometimes miss small cancers, delaying diagnosis and treatment.
The scientists' search for better ways of diagnosis led them to a new group of radioactive imaging agents, called fluoronicotinamides, which they tested in laboratory mice that had melanoma.
The most promising substance revealed melanoma cells with greater accuracy than imaging agents now in use, the scientists note. As a result, this substance could become a "superior" PET imaging agent for improving the diagnosis and monitoring the effectiveness of treatment of melanoma, they say. Clinical trials with this new agent are now scheduled for 2010.
###
ARTICLE #2 FOR IMMEDIATE RELEASE
"Discovery of [18F]N-(2-(Diethylamino)ethyl)-6-fluoronicotinamide: A Melanoma Positron Emission Tomography Imaging Radiotracer with High Tumor to Body Contrast Ratio and Rapid Renal Clearance"
DOWNLOAD FULL TEXT ARTICLE http://pubs.acs.org/stoken/presspac/presspac/full/10.1021/jm9008423
CONTACT:
Ivan Greguric, Ph.D.
Radiopharmaceuticals Research Institute
Australian Nuclear Science and Technology Organization
Sydney, Australia
Phone: 61-2-9717 3759
Fax: 61-2-9717-9262
Email: [email protected]
Contact: Michael Woods
[email protected]
202-872-6293
American Chemical Society
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Cancer →
GuideScreening with Other Imaging Modalities: Early Investigations
Ultrasound Several investigators are evaluating the use of ultrasound to detect breast cancer that cannot be seen with mammography. Because ultrasound cannot reliably identify microcalcifications, which are…
14 June 2008
NewsEarly Diagnosis of Lung Cancer: Where Do We Stand?
Lung cancer is the leading cause of cancer deaths worldwide [1] ; approximately 85% of all lung cancers occur in current or former cigarette smokers [2] . Recently, two important studies [3, 4] received worldwide press…
7 May 2008
NewsPreoperative assessment of cancer patients enables early diagnosis, treatment of lymphedema
The preoperative assessment of breast cancer patients for subclinical lymphedema enables clinicians to establish a baseline, which serves to enable the early diagnosis and successful treatment of the debilitating…
